Psychedelic Medicines in Major Depression: Progress and Future Challenges.
Study Goal
The researchers aimed to review the safety, efficacy, and neurobiological mechanisms of psychedelic drugs, including ayahuasca, for treating mental disorders such as major depression.
Results Summary
The abstract indicates that clinical trials have assessed ayahuasca's therapeutic potential, suggesting it may be effective as an adjuvant in psychotherapeutic processes, though specific results are not detailed.
Population
Patients with mental disorders, including major depression (specific demographics not provided).
Effective Dosage
Not specified
Duration
Not specified
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
psilocybin | neutral | major depression | patients | - | assessed the safety and efficacy | #1 |
ayahuasca | neutral | major depression | patients | - | assessed the safety and efficacy | #2 |
The volume of research on the therapeutic use of psychedelic drugs has been increasing during the last decades. Partly because of the need of innovative treatments in psychiatry, several studies have assessed the safety and efficacy of drugs like psilocybin or ayahuasca for a wide range of mental disorders, including major depression. The first section of this chapter will offer an introduction to psychedelic research, including a brief historical overview and discussions about appropriate terminology. In the second section, the recently published clinical trials in which psychedelic drugs were administered to patients will be analysed in detail. Then, in the third section, the main neurobiological mechanisms of these drugs will be described, noting that while some of these mechanisms could be potentially associated with their therapeutic properties, they are commonly used as adjuvants in psychotherapeutic processes. The last section suggests future challenges for this groundbreaking field of research and therapy.